表紙
市場調査レポート

疼痛管理の薬理学的治療と機器による治療:米国市場

U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management

発行 Medtech Insight 商品コード 204529
出版日 ページ情報 英文 192 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
疼痛管理の薬理学的治療と機器による治療:米国市場 U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management
出版日: 2014年06月01日 ページ情報: 英文 192 Pages
概要

米国における疼痛管理製品の総市場は、2013年の364億ドルから2018年には447億ドルに拡大すると予測されています。総売上のうち、92%以上は医薬品が占め、残りの8%が疼痛管理デバイスとなっています。

当レポートでは、米国における疼痛管理のための医薬品および機器の市場について調査し、疼痛の各種タイプ、臨床的アプローチの種類と概要、米国における有病率、医薬品および機器の市場成長予測(薬剤・機器タイプ別)、サプライヤーの市場シェア、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 疼痛管理の概要

  • 疼痛の生理学
    • 神経系
    • 痛みの認知
    • 疼痛分類
  • 疼痛評価技術
  • 有病率
  • 一般的な疼痛症候群
    • 関節炎性疼痛
    • 背痛
    • 熱傷疼痛
    • 癌性疼痛
    • 頭痛
    • HIV・エイズ性疼痛
    • 陣痛
    • 坐骨神経痛
    • 顎関節疼痛
    • 外傷性疼痛、など
  • 臨床的アプローチ
    • 疼痛管理ガイドライン
    • 高齢者に対する疼痛管理ガイドライン
    • 介入的疼痛管理ガイドライン
    • 疼痛管理の選択肢

第2章 疼痛管理医薬品

  • 医薬品の製剤とドラッグデリバリー
    • 経口投与
    • 注射・注入
    • 吸入
    • 経皮
    • 経粘膜
    • 非ステロイド抗炎症剤
  • アスピリンの利点
    • 心臓発作/脳梗塞予防
    • 心不全
    • 癌予防
  • 市場分析
    • 非処方鎮痛剤/麻酔剤
    • 非処方局所用鎮痛剤/麻酔剤
    • 処方鎮痛剤/麻酔剤
    • 市場予測

第3章 疼痛管理機器

  • 電気刺激
  • 鎮痛剤注入ポンプ
  • 市場予測

第4章 企業プロファイル

  • AstraZeneca PLC
  • Baxter Healthcare, Inc./Baxter International, Inc.
  • Bayer HealthCare AG/Bayer AG
  • Boston Scientific Corporation
  • CareFusion Corporation
  • Chattem, Inc./sanofi-aventis LLC
  • DJO Global, Inc.
  • Eli Lilly and Company
  • Endo Pharmaceutical Holdings, Inc./Endo International PLC
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • International Rehabilitative Sciences, Inc., d/b/a RS Medical
  • Johnson & Johnson
  • Medtronic, Inc.
  • Pfizer, Inc.
  • Purdue Pharma LP
  • Teva Pharmaceutical Industries LTD

企業リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: A374

Pain is the single most common reason patients seek medical care, accounting for approximately half of all physician office visits in the United States (U.S.); some studies suggest that more than one-third of people in the U.S. suffer from a chronic pain condition at some point in their lives.

This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).

During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.

Table of Contents

EXECUTIVE SUMMARY

  • i. Pain Management Pharmaceuticals
    • a. Nonprescription Analgesics and Anesthetics
      • i. Nonprescription Systemic Analgesics
      • ii. Nonprescription Topical Analgesics
      • iii. Market Forecast
    • b. Prescription Analgesics and Anesthetics
      • i. Prescription Non-Steroidal Anti-Inflammatory Drugs
      • ii. Opioid Analgesics
      • iii. Opioid/Nonopioid Combination Analgesics
      • iv. Antimigraine Analgesics
      • v. Adjuvant Analgesics
      • vi. General, Regional, and Local Anesthetics
      • vii.. Market Forecast
    • c. Combined Market Forecast
      • ii. Pain Management Devices
    • a. Electrical Stimulators
      • i. Transcutaneous Electrical Nerve Stimulators
      • ii. Neurostimulators
      • iii. Market Forecast
    • b. Analgesia Infusion Pumps
      • i. Implantable Analgesia Infusion Pumps
      • ii. External Analgesia Infusion Pumps
      • iii. Market Forecast
    • c. Combined Market Forecast
      • iii. Combined Market Forecast
  • Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018
  • Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018

1. PAIN MANAGEMENT OVERVIEW

  • 1.1. Pain Physiology
    • 1.1.1. The Nervous System
    • 1.1.2. Pain Perception
    • 1.1.3. Pain Classification
      • 1.1.3.1. Nociceptive Pain
      • 1.1.3.2. Non-Nociceptive Pain
      • 1.1.3.3. Acute Pain
      • 1.1.3.4. Chronic Pain
  • 1.2. Pain Assessment Techniques
  • 1.3. Pain Prevalence
  • 1.4. Common Pain Syndromes
    • 1.4.1. Arthritis Pain
    • 1.4.2. Back Pain
    • 1.4.3. Burn Pain
    • 1.4.4. Cancer Pain
    • 1.4.5. Headache Pain
    • 1.4.6. Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain
    • 1.4.7. Obstetric Pain
    • 1.4.8. Podiatric Pain
    • 1.4.9. Sciatic Pain
    • 1.4.10. Temporomandibular Pain
    • 1.4.11. Trauma Pain
  • 1.5. Clinical Approaches to Pain Management
    • 1.5.1. Pain Management Guidelines
    • 1.5.2. Pain Management Guidelines for Older Adults
    • 1.5.3. Interventional Pain Management Guidelines
    • 1.5.4. Pain Management Options
      • 1.5.4.1. Pharmaceutical Options
      • 1.5.4.2. Device-Based Options
      • 1.5.4.3. Alternative Therapy Options
  • Exhibit 1-1: Common Causes of Neuropathic Pain
  • Exhibit 1-2: United States Population, by Selected Ages, 1990-2050
  • Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management

2. PAIN MANAGEMENT PHARMACEUTICALS

  • 2.1. Pharmaceutical Formulations and Drug Delivery
    • 2.1.1. Oral Drug Delivery
    • 2.1.2. Injection/Infusion Drug Delivery
      • 2.1.2.1. Injection
        • 2.1.2.1.1. Intramuscular Injection
        • 2.1.2.1.2. Subcutaneous Injection
      • 2.1.2.2. Infusion
        • 2.1.2.2.1. Intravenous Infusion
        • 2.1.2.2.2. Intraspinal Infusion
        • 2.1.2.2.3. Intraoperative Site Infusion
    • 2.1.3. Inhalation Drug Delivery
    • 2.1.4. Transdermal Drug Delivery
    • 2.1.5. Transmucosal Drug Delivery
    • 2.1.6. Nonsteroidal Anti-Inflammatory Drugs
      • 2.1.6.1. Heart Attack and Hypertension Risks
      • 2.1.6.2. The Food and Drug Administration and Labeling
      • 2.1.6.3. Naproxen Risks
  • 2.2. The Benefits of Aspirin
    • 2.2.1. Aspirin and Heart Attack/Stroke Prevention
    • 2.2.2. Aspirin and Heart Failure
    • 2.2.3. Aspirin and Cancer Prevention
  • 2.3. Market Analysis
    • 2.3.1. Nonprescription Analgesics and Anesthetics
      • 2.3.1.1. Market Forecast
      • 2.3.1.2. Nonprescription Systemic Analgesics
        • 2.3.1.2.1. Acetaminophen
        • 2.3.1.2.2. Nonprescription Nonsteroidal Anti-Inflammatory Drugs
        • 2.3.1.2.3. Market Forecast
        • 2.3.1.2.4. Competitive Analysis
    • 2.3.1.3. Nonprescription Topical Analgesics and Anesthetics
      • 2.3.1.3.1. Amino Amides and Esters
      • 2.3.1.3.2. Capsaicin
      • 2.3.1.3.3. Methyl and Trolamine Salicylates
      • 2.3.1.3.4. Topical Patches
      • 2.3.1.3.5. Market Forecast
      • 2.3.1.3.6. Competitive Analysis
    • 2.3.2. Prescription Analgesics and Anesthetics
      • 2.3.2.1. Market Forecast
      • 2.3.2.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
        • 2.3.2.2.1. Acetic Acid Derivatives
        • 2.3.2.2.2. Anthranilic Acid Derivatives
        • 2.3.2.2.3. Cyclooxygenase-2 Selective Inhibitors
        • 2.3.2.2.4. Enolic Acid Derivatives
        • 2.3.2.2.5. Propionic Acid Derivatives
        • 2.3.2.2.6. Salicylic Acid Derivatives
        • 2.3.2.2.7. Market Forecast
        • 2.3.2.2.8. Competitive Analysis
      • 2.3.2.3. Opioid Analgesics
        • 2.3.2.3.1. Buprenorphine
        • 2.3.2.3.2. Butorphanol
        • 2.3.2.3.3. Codeine
        • 2.3.2.3.4. Fentanyl
        • 2.3.2.3.5. Hydromorphone
        • 2.3.2.3.6. Levorphanol
        • 2.3.2.3.7. Meperidine
        • 2.3.2.3.8. Morphine
        • 2.3.2.3.9. Nalbuphine
        • 2.3.2.3.10. Oxycodone
        • 2.3.2.3.11. Oxymorphone
        • 2.3.2.3.12. Pentazocine
        • 2.3.2.3.13. Propoxyphene
        • 2.3.2.3.14. Remifentanil
        • 2.3.2.3.15. Tramadol
        • 2.3.2.3.16. Tapentadol
        • 2.3.2.3.17. Hydrocodone
        • 2.3.2.3.18. Market Forecast
        • 2.3.2.3.19. Competitive Analysis
      • 2.3.2.4. Opioid/Nonopioid Combination Analgesics
        • 2.3.2.4.1. Market Forecast
        • 2.3.2.4.2. Competitive Analysis
      • 2.3.2.5. Antimigraine Analgesics
        • 2.3.2.5.1. Diclofenac
        • 2.3.2.5.2. Dihydroergotamine
        • 2.3.2.5.3. Divalproex Sodium
        • 2.3.2.5.4. Triptans
        • 2.3.2.5.5. Market Forecast
        • 2.3.2.5.6. Competitive Analysis
      • 2.3.2.6. Adjuvant Analgesics
        • 2.3.2.6.1. Anticonvulsants
        • 2.3.2.6.2. Antidepressants
        • 2.3.2.6.3. Corticosteriods
        • 2.3.2.6.4. Market Forecast
        • 2.3.2.6.5. Competitive Analysis
      • 2.3.2.7. General, Regional, and Local Anesthetics
        • 2.3.2.7.1. Inhalation General Anesthetics
        • 2.3.2.7.2. Intravenous General Anesthetics
        • 2.3.2.7.3. Anesthetics Used in Balanced Anesthesia
        • 2.3.2.7.4. Regional/Local Anesthetics
        • 2.3.2.7.5. Market Forecast
        • 2.3.2.7.6. Competitive Analysis
    • 2.3.3. Combined Market Forecast
  • Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods
  • Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics
  • Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics
  • Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018
  • Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier
  • Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier
  • Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018
  • Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier
  • Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier
  • Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier
  • Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018
  • Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier
  • Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018
  • Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier
  • Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018

3. PAIN MANAGEMENT DEVICES

  • 3.1. Electrical Stimulators
    • 3.1.1. Transcutaneous Electrical Nerve Stimulators
      • 3.1.1.1. Market Forecast
      • 3.1.1.2. Competitive Analysis
    • 3.1.2. Neurostimulators
      • 3.1.2.1. Occipital Nerve Stimulation
      • 3.1.2.2. Neuromuscular Stimulators
      • 3.1.2.3. Spinal Cord and Peripheral Nerve Stimulators
      • 3.1.2.4. Market Forecast
      • 3.1.2.6. Competitive Analysis
  • 3.2. Analgesia Infusion Pumps
    • 3.2.1. Implantable Analgesia Infusion Pumps
      • 3.2.1.1. Market Forecast
      • 3.2.1.2. Competitive Analysis
    • 3.2.2. External Analgesia Infusion Pumps
      • 3.2.2.1. Nerve Block
      • 3.2.2.2. Patient-Controlled Analgesia Infusion Pumps
      • 3.2.2.3. Products
      • 3.2.2.4. Market Forecast
      • 3.2.2.5. Competitive Analysis
  • 3.3. Combined Market Forecast
  • Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder
  • Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy
  • Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018
  • Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
  • Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018
  • Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier
  • Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier
  • Exhibit 3-8: Implantable Analgesia Infusion Pumps, Market Forecast, 2013-2018
  • Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier
  • Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018
  • Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier
  • Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018

4. COMPANY PROFILES

  • 4.1. AstraZeneca PLC
  • 4.2. Baxter Healthcare, Inc./Baxter International, Inc.
  • 4.3. Bayer HealthCare AG/Bayer AG
  • 4.4. Boston Scientific Corporation
  • 4.5. CareFusion Corporation
  • 4.6. Chattem, Inc./sanofi-aventis LLC
  • 4.7. DJO Global, Inc.
  • 4.8. Eli Lilly and Company
  • 4.9. Endo Pharmaceutical Holdings, Inc./Endo International PLC
  • 4.10. GlaxoSmithKline PLC
  • 4.11. Hospira, Inc.
  • 4.12. International Rehabilitative Sciences, Inc., d/b/a RS Medical
  • 4.13. Johnson & Johnson
  • 4.14. Medtronic, Inc.
  • 4.15. Pfizer, Inc.
  • 4.16. Purdue Pharma LP
  • 4.17. Teva Pharmaceutical Industries LTD

APPENDIX: COMPANY LISTING

Back to Top